Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Rawalpindi Medical College
- Target Recruit Count
- 1209
- Registration Number
- NCT05931042
- Locations
- 🇵🇰
Rawalpindi Medical University, Rawalpindi, Punjab, Pakistan
DP303c in Patients With HER2-positive Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 420
- Registration Number
- NCT05901935
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 370
- Registration Number
- NCT05900206
- Locations
- 🇸🇪
Stockholm Southern Hospital, Stockholm, Sweden
🇸🇪Skåne University Hospital, Malmö, Sweden
🇸🇪Sankt Gorans Hospital, Stockholm, Sweden
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1406
- Registration Number
- NCT05883852
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 876
- Registration Number
- NCT05841381
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 880
- Registration Number
- NCT05838066
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 30
- Registration Number
- NCT05786716
- Locations
- 🇬🇧
Bristol Royal Hospital for Children, Bristol, United Kingdom
🇬🇧Great North Children's Hospital, Newcastle, United Kingdom
🇬🇧Belfast City Hospital, Belfast, United Kingdom
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 287
- Registration Number
- NCT05785741
- Locations
- 🇺🇸
Research Site 111, Atlanta, Georgia, United States
🇺🇸University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05725200
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 560
- Registration Number
- NCT05720026
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.